Completed PHASE2 INTERVENTIONAL 1-arm NCT00088205

Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma

A Phase 2 Study of Oral Enzastaurin HCl in Patients With Relapsed Mantle Cell Lymphoma

Sponsor: Eli Lilly and Company

Interventions enzastaurin

Updated 8 times since 2017 Last updated: Jun 9, 2020 Started: Mar 31, 2004 Primary completion: May 31, 2008 Completion: May 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00088205, this PHASE2 trial focuses on Mantle-Cell Lymphoma and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Aug 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Aug 2020 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Cologne, Germany , Créteil, France , East Melbourne, Australia , Groningen, Netherlands , Homburg Saar, Germany , Kassel, Germany , Lille, France , Nantes, France , Nijmegen, Netherlands and 7 more locations